Detalhe da pesquisa
1.
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Br J Dermatol
; 188(6): 740-748, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36994947
2.
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
J Eur Acad Dermatol Venereol
; 37(5): 1036-1045, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36514996
3.
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials.
Br J Dermatol
; 186(6): 1047-1049, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35041213
4.
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes.
Dermatol Ther
; 35(12): e15954, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36270978
5.
Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
J Cutan Med Surg
; 26(3): 262-266, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086348
6.
Patient-Reported Disease Burden and Unmet Therapeutic Needs in Atopic Dermatitis.
J Drugs Dermatol
; 20(11): 1222-1230, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34784136
7.
Treatment of adult atopic dermatitis patients according to disease characteristics and demographics.
Dermatol Ther
; 33(6): e14439, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33084105
8.
Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Dig Dis Sci
; 65(9): 2675-2685, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31925675
9.
Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study.
J Drugs Dermatol
; 19(10): 943-948, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026770
10.
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
Br J Dermatol
; 190(2): 289-291, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939793
11.
Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom.
Dermatol Ther (Heidelb)
; 14(5): 1103-1114, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38652379
12.
Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
Adv Ther
; 41(4): 1512-1525, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38363461
13.
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials.
J Dermatolog Treat
; 35(1): 2329240, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38679419
14.
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
J Dermatolog Treat
; 35(1): 2324833, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38735650
15.
The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata.
Dermatol Ther (Heidelb)
; 13(7): 1503-1515, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289409
16.
Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
J Dermatolog Treat
; 34(1): 2190430, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36912484
17.
Burden of adult atopic dermatitis and unmet needs with existing therapies.
J Dermatolog Treat
; 34(1): 2202288, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042571
18.
Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
J Dermatolog Treat
; 34(1): 2227299, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381691
19.
Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry.
J Dermatolog Treat
; 34(1): 2246601, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691405
20.
Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry.
Dermatol Ther (Heidelb)
; 13(9): 2045-2061, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37481484